Hubei Goto Biopharm Co.,Ltd.

SZSE:300966.SZ

21.06 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q4
Revenue 111.255122.228181.361117.217148.398119.423157.748178.476147.896120.451144.935143.271160.852141.827148.625117.424165.1436.929111.599
Cost of Revenue 100.86895.866144.9288.284112.69395.382124.912141.999111.44887.993105.838107.408117.025104.704112.649-157.507126.49231.0140
Gross Profit 10.38726.36236.44128.93335.70524.04232.83636.47736.44832.45839.09735.86343.82737.12435.976274.9338.6475.915111.599
Gross Profit Ratio 0.0930.2160.2010.2470.2410.2010.2080.2040.2460.2690.270.250.2720.2620.2422.3410.2340.161
Reseach & Development Expenses 9.2989.5057.7839.27910.49110.54615.61712.5628.0778.89212.61111.7436.1896.5810.724.4684.1952.2210
General & Administrative Expenses 0.23113.028-18.06127.762-3.08910.148-12.30219.706-0.2187.889-9.69119.8750.8657.4814.223.805-18.6363.4340
Selling & Marketing Expenses 1.6060.8653.4131.2271.5560.8682.3260.7370.9430.9012.3020.8891.2541.0260.7330.791.3560.5740
SG&A 15.28613.893-14.64828.989-1.53311.016-9.97620.4440.7258.79-7.38820.7642.1198.5061.7015.608-17.284.0080
Other Expenses 4.57-0.3-3.8890.095-0.9854.365-3.0522.3810.2360.04615.6380.6036.7070.457-124.817-260.02616.287-0.024-100.337
Operating Expenses 20.01421.48417.90122.37621.39921.67926.9423.2817.81217.25829.39519.99918.92715.152-124.817-260.02611.1066.031-100.337
Operating Income -9.6272.2354.4444.09111.983-0.989-2.71112.62514.98514.00510.00411.87823.17917.6523.80814.90520.767-2.17911.261
Operating Income Ratio -0.0870.0180.0250.0350.081-0.008-0.0170.0710.1010.1160.0690.0830.1440.1240.160.1270.126-0.0590.101
Total Other Income Expenses Net -4.02-0.3-3.8890.095-0.9854.365-3.0522.3810.2360.04615.6380.6036.7070.4570.662-0.4842.788-0.0242.697
Income Before Tax -13.6471.9360.5564.18610.9993.376-5.76315.00515.22114.05125.64212.48129.88718.10724.46914.42123.555-2.20313.958
Income Before Tax Ratio -0.1230.0160.0030.0360.0740.028-0.0370.0840.1030.1170.1770.0870.1860.1280.1650.1230.143-0.060.125
Income Tax Expense -3.499-0.9570.642-0.558-1.982-0.275-5.8782.2931.3281.2741.403-0.54.172.9792.4711.8122.67-1.9870.497
Net Income -8.6663.5470.2215.31213.4484.0240.2712.93713.93613.04424.26513.02225.76615.27721.99812.60820.885-2.20313.461
Net Income Ratio -0.0780.0290.0010.0450.0910.0340.0020.0720.0940.1080.1670.0910.160.1080.1480.1070.126-0.060.121
EPS -0.0750.030.050.0460.120.0350.0020.110.120.110.210.10.240.180.260.140.22-0.030
EPS Diluted -0.0750.030.050.0460.120.0350.0020.110.110.110.210.10.240.180.260.140.22-0.030
EBITDA -1.84.94314.8326.72915.1047.7592.34917.84320.05915.42425.67416.59731.47921.498-245.748278.42140.9780.092-247.047
EBITDA Ratio -0.0160.040.0820.0570.1020.0650.0150.10.1360.1280.1770.1160.1960.152-1.6532.3710.2480.002-2.214